Cardiomyopathy in AIDS: A pathophysiological perspective

Progress in Cardiovascular Diseases

Volumn 43, Issue 2, 2000, Pages 151-170

  Lewis, William ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; COCAINE; CYTOKINE; DIDANOSINE; ENDOTHELIN 1; FIALURIDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL ABUSE; ANTIVIRAL ACTIVITY; CARDIOMYOPATHY; CAUSE OF DEATH; COMORBIDITY; DRUG ABUSE; EPIDEMIOLOGICAL DATA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN IMMUNODEFICIENCY VIRUS 1; MYOCARDITIS; PATHOGENESIS; REVIEW; SURVIVAL; TRANSGENIC MOUSE;

EID: 0033830313     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2000.9031     Document Type: Article

References (226)

1. Prevalence of HIV infection in the United States, 1984 to 1992
2. Effect of HIV/AIDS versus other causes of death on premature mortality in New York City, 1983-1994
3. Causes of death in homeless adults in Boston
4. Premature mortality in Italy during the first decade of the AIDS epidemic: 1984-1993
5. Trends of morbidity in general medicine at United Bulawayo Hospitals, Bulawayo, Zimbabwe
6. Characteristics of human immunodeficiency virus-infected children at the time of death: An experience in the 1990s
7. AIDS giving rise to cardiac problems
8. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection
9. Cardiac involvement in human immunodeficiency virus infection
10. AIDS cardiomyopathy
11. HIV cardiomyopathy: A dark cloud with a silver lining?
12. Emerging patterns of heart disease in HIV infected homosexual subjects with and without opportunistic infections: A prospective colour flow Doppler echocardiographic study
13. Emerging patterns of heart disease in human immunodeficiency virus infection
14. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
15. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
16. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome
17. Congestive cardiomyopathy in association with AIDS
18. Outcome of intensive care in patients with HIV infection
19. Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: A serial echocardiographic study
20. Myocardial dysfunction in patients infected with HIV: Prevalence and risk factors
21. Dilated cardiomyopathy in haemophiliacs infected with the human immunodeficiency virus
22. AIDS cardiomyopathy: First rule out other myocardial risk factors
23. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS
24. Dilated cardiomyopathy in HIV-infected patients
25. Dilated cardiomyopathy in HIV-infected patients
26. Dilated cardiomyopathy in HIV-infected patients
27. The causes of dilated cardiomyopathy: A clinicopathologic review of 673 consecutive patients
28. Cardiomyopathy associated with the acquired immune deficiency syndrome
29. Clinical, echocardiographic, and electrocardiographic resolution of HIV-related cardiomyopathy
30. Unsuspected cardiac abnormalities in the acquired immune deficiency syndrome. An echocardiographic study
31. Alcoholic cardiomyopathy. Concept of the disease and its treatment
32. Electron microscopic observations on lysosomes and related cytoplasmic components of normal and pathological cardiac muscle
33. Myocardial function and lipid metabolism in the chronic alcoholic animal
34. Progression of myocardial abnormalities in experimental alcoholism
35. Reversibility of mitochondrial and contractile changes in the myocardium after cessation of prolonged ethanol intake
36. Effects of chronic graded ethanol consumption on the metabolism, ultrastructure, and mechanical function of the rat heart
37. Biochemical and contractile properties of heart muscle after prolonged alcohol administration
38. Effect of alcohol on the heart and cardiac metabolism
39. Alcohol and the heart
40. Alcoholic myopathy in heart and skeletal muscle
41. Alcoholic cardiomyopathy
42. The effect of ethanol and acetaldehyde on Na pump function in cultured rat heart cells
43. Experimental models for studying the effects of ethanol on the myocardium
44. Alcohol-induced cardiac hemodynamic and Ca2+ flux dysfunctions are reversible
45. The effects of chronic ethanol consumption on cardiac function in rats
46. Left ventricular dysfunction induced by chronic alcohol ingestion in rats
47. Suppression of ethanol-induced cardiac hypertrophy by beta-adrenoceptor blockade
48. Ventricular loading is coupled with DNA synthesis in adult cardiac myocytes after acute and chronic myocardial infarction in rats
49. The heart in chronic alcoholism: A noninvasive study
50. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure
51. The effects of alcoholism on skeletal and cardiac muscle
52. Ventricular function in noncardiacs with alcoholic fatty liver: Role of ethanol in the production of cardiomyopathy
53. Prevalence of clinically occult cardiomyopathy in chronic alcoholism
54. Effects of ethanol on the contractile function of the heart: A review
55. Chronic alcohol-induced changes in cardiac contractility are not due to changes in the cytosolic Ca2+ transient
56. Spatial and temporal distribution of cocaine and effects of pharmacological interventions: Wholebody autoradiographic microimaging studies
57. Distribution and kinetics of carbon-11-cocaine in the human body measured with PET
58. Metabolism of cocaine in man
59. Effect of cocaine and cocaine metabolites on cerebral arteries in vitro
60. Comparison of the effects of cocaine and its metabolites on cardiovascular function in anesthetized rats
61. Hemodynamic and cerebral blood flow effects of cocaine, cocaethylene and benzoylecgonine in conscious and anesthetized fetal lambs
62. Effects of cocaine, benzoylecgonine, and cocaine metabolites in cannulated pressurized fetal sheep cerebral arteries
63. Left ventricular hypertrophy associated with chronic cocaine abuse
64. Left ventricular hypertrophy in normotensive cocaine users
65. Lack of association of recreational cocaine and alcohol use with left ventricular mass in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) study
66. Left ventricular morphologic features and function in non-hospitalized cocaine users: A quantitative two-dimensional echocardiographic study
67. Myocardial hypertrophy and coronary artery disease in male cocaine users
68. Frequency and type of electrocardiographic abnormalities in cocaine abusers (electrocardiogram in cocaine abuse)
69. Cardiovascular effects and toxicities of cocaine
70. Coronary artery disease, left ventricular hypertrophy, and the risk of cocaine overdose death
71. Sarcoid cardiomyopathy precipitated by pregnancy with cocaine complications
72. Dilated cardiomyopathy and cocaine abuse. Report of two cases
73. Reversible cardiomyopathy associated with cocaine intoxication
74. Chronic cocaine abuse and dilated cardiomyopathy
75. Chronic cocaine abuse associated with dilated cardiomyopathy
76. Postpartum cardiomyopathy associated with maternal cocaine abuse
77. Myocardial contraction bands revisited
78. Direct cocaine cardiotoxicity demonstrated by endomyocardial biopsy
79. Apparent reversibility of cocaine-induced congestive cardiomyopathy
80. L-norepinephrine myocarditis
81. Effects of adrenergic receptor antagonists on cardiac morphological and functional alterations in rats harboring pheochromocytoma
82. The pathology and etiology of cocaine-induced heart disease
83. Acute cardiac events temporally related to cocaine abuse
84. Cardiovascular effects of cocaine: An autopsy study of 40 patients
85. Structural remodeling in hypertensive heart disease and the role of hormones
86. Tumor necrosis factor-alpha and cardiomyopathy
87. Cocaine increases the endothelial release of immunoreactive endothelin and its concentrations in human plasma and urine: Reversal by coincubation with sigma-receptor antagonists
88. Atrial natriuretic factor and related peptide hormones
89. Review articles: Mechanisms of disease: Signaling pathways for cardiac hypertrophy and failure
90. Preformed natural antibodies: Their impact on contractile activity of cardiomyocytes
91. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta
92. Negative inotropic cascades in cardiomyocytes triggered by substances relevant to sepsis
93. Mechanisms of immune-mediated myocyte injury
94. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness
95. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs
96. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study
97. Molecular and cellular mechanisms of myocardial failure
98. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation
99. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy
100. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
101. Endothelin in human congestive heart failure
102. Role of endothelin in the exercise intolerance of chronic heart failure
103. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
104. Interleukin-6 (IL-6) as a mediator of stunned myocardium
105. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery
106. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA)
107. Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy
108. Mechanisms of endocardial endothelium modulation of myocardial performance
109. Endocardial endothelial dysfunction and heart failure
110. Aortic endothelium in HIV-1 infection: Chronic injury, activation, and increased leukocyte adherence
111. Infection of the retina by human immunodeficiency virus type I
112. Productive in vitro infection of human umbilical vein endothelial cells and three colon carcinoma cell lines with HIV-1
113. Upregulation of human immunodeficiency virus-1 in chronically infected monocytic cell line by both contact with endothelial cells and cytokines
114. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1 beta plus tumor necrosis factor-alpha
115. HIV-1: Fifteen proteins and an RNA
116. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and inter-cellular adhesion molecule-1 in human endothelial cells
117. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
118. Angiogenic properties of human immunodeficiency virus type 1 Tat protein
119. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS
120. The biochemistry of AIDS
121. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
122. HIV-1 transactivator protein Tat induces proliferation and TGF beta expression in human articular chondrocytes
123. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis
124. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells
125. Mitochondrial toxicity of antiviral drugs
126. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts
127. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria
128. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model
129. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with Zidovudine
130. Diseases of the mitochondrial DNA
131. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine
132. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU Triphosphate
133. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts
134. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax)
135. Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells
136. Mitochondrial toxicity - New adverse drug effects
137. HIV nucleoside analogues: New adverse effects on mitochondria?
138. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
139. Zidovudine (AZT) induced alterations in mitochondrial biogenesis in rat striated muscles
140. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat
141. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases
142. Altered distribution of desmin filaments in hypertrophic cardiomyopathy: An immunohistochemical study
143. Mitochondrial cardiomyopathy in HIV-1 patients with zidovudine
144. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero
145. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys
146. Left ventricular structure and function in children infected with human immunodeficiency virus: The prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group
147. Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient
148. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma
149. Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
150. Torsade de pointes during administration of pentamidine isethionate
151. HIV-protease inhibitors
152. Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection
153. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection
154. Cardiac involvement in human immunodeficiency virus-infected patients
155. L-carnitine deficiency in AIDS patients
156. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction
157. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus
158. Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS)
159. Reduced cardiac selenium content in the acquired immunodeficiency syndrome
160. Selenium deficiency and cardiomyopathy in acquired immunodeficiency syndrome
161. Myocarditis diagnosed by endomyocardial biopsy in human immunodeficiency virus infection with cardiac dysfunction
162. Pathology of the heart in AIDS. A study of 60 consecutive autopsies
163. Cardiac function in patients with human immunodeficiency virus infection and with no other active infections
164. Pathology of the heart in acquired immunodeficiency syndrome (AIDS)
165. Opportunistic invasion of the heart in Hispanic patients with acquired immunodeficiency syndrome
166. Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome
167. AIDS and the heart: Review and consideration of pathogenetic mechanisms
168. Focal lymphocytic myocarditis in acquired immunodeficiency syndrome (AIDS): A correlative morphologic and clinical study in 26 consecutive fatal cases
169. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome
170. Pathology of the heart in acquired immunodeficiency syndrome
171. Leukocytic infiltrates in idiopathic dilated cardiomyopathy. A source of confusion with active myocarditis
172. Cardiac lesions in acquired immune deficiency syndrome (AIDS)
173. AIDS: Cardiac findings from 115 autopsies
174. Incidental myocarditis with intravenous drug abuse: The pathology, immunopathology, and potential implications for human immunodeficiency virus-associated myocarditis
175. Acquired immune deficiency syndrome: The heart of the matter
176. Myocardial risk factors other than human immunodeficiency virus infection may contribute to histologic cardiomyopathic changes in acquired immune deficiency syndrome
177. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy
178. Fifty cases of human immunodeficiency virus (HIV) infection: Immunoultrastructural study of circulating lymphocytes
179. Isolation of the human T-cell leukemia/lymphotropic virus type III from the cornea
180. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients
181. Acute HIV infection presenting with painful swallowing and esophageal ulcers
182. Sensory motor neuropathy associated with AIDS
183. Detection of HIV-related protein in testes and prostates of patients with AIDS
184. The value of the autopsy for the 1990s
185. HIV receptors (CD4 antigen) in normal human glomerular cells
186. Left ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: An echocardiographic study
187. SIV in non-human primates causes myocardial injury and cardiomyopathy following chronic but not acute infection
188. Human immunodeficiency virus, coxsackievirus, and cardiomyopathy
189. Infection of the heart by the human immunodeficiency virus
190. Macrophages not cardiac myocytes are the reservoir for lentivirus in SIV cardiomyopathy
191. Dilated cardiomyopathy associated with Simian AIDs in non-human primates
192. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome
193. Identification of human immunodeficiency virus in the heart of a patient with acquired immunodeficiency syndrome
194. Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium
195. Proliferative membranopathy and human immunodeficiency virus in AIDS hearts
196. HIV-associated myocarditis. Pathology and immunopathology
197. New concepts in the immunopathogenesis of human immunodeficiency virus infection
198. Biologic features of HIV-1 that correlate with virulence in the host
199. The early region of human papovavirus JC induces dysmyelination in transgenic mice
200. A transgenic mouse model for human neurofibromatosis
201. Exocrinopathy resembling Sjogren's syndrome in HTLV-1 tax transgenic mice
202. HBx gene of hepatitis B virus induces liver cancer in transgenic mice
203. Transgenic models of human immunodeficiency virus type-1
204. Transgenic dissection of HIV genes involved in lymphoid depletion
205. Molecular and ultrastructural features of cardiomyopathy occur in AIDS transgenic (TG) mice treated with zidovudine
206. Simian immunodeficiency virus as a model of HIV pathogenesis
207. Confronting the HIV pandemic
208. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome
209. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus
210. Clinical and laboratory findings in cats infected with feline immunodeficiency virus
211. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats
212. Early suppression of viremia by ZDV does not alter the spread of feline immunodeficiency virus infection in cats
213. Early events in the immunopathogenesis of feline retrovirus infections
214. Isolation of a T-lymphotropic lentivirus from a persistently leucopenic domestic cat
215. Feline leukemia virus and feline immunodeficiency virus infections in a cat with lymphoma
216. Evaluation of in vivo and in vitro interactions of feline immunodeficiency virus and feline leukemia virus
217. Development of clinical disease in cats experimentally infected with feline immunodeficiency virus
218. Nucleotide sequence analysis of feline immunodeficiency virus: Genome organization and relationship to other lenti-viruses
219. Molecular cloning of feline immunodeficiency virus
220. Nucleotide sequence and genomic organization of feline immunodeficiency virus
221. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome
222. Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses
223. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase